ShRNA screening identifies JMJD1C as being required for leukemia maintenance

Blood

Volumn 123, Issue 12, 2014, Pages 1870-1882

  Sroczynska, Patrycja ^a,b   Cruickshank, V Adam ^a,b   Bukowski, John Paul ^a,b   Miyagi, Satoru ^a,b   Bagger, Frederik Otzen ^a,b   Walfridsson, Julian ^d   Schuster, Mikkel Bruhn ^a,b,c   Porse, Bo ^a,b,c   Helin, Kristian ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c FINSEN LABORATORY   (Denmark)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

JMJD1C PROTEIN; ONCOPROTEIN; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CELL SURVIVAL; COLONY FORMATION; CONTROLLED STUDY; FUSION GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; MOUSE; NONHUMAN; ONCOGENE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEPLETION; REGULATORY MECHANISM; SCREENING;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; EPIGENESIS, GENETIC; GENE KNOCKDOWN TECHNIQUES; GENES, MYB; GENES, MYC; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; JUMONJI DOMAIN-CONTAINING HISTONE DEMETHYLASES; LEUKEMIA, EXPERIMENTAL; LEUKEMIA, MYELOID, ACUTE; MICE; MYELOID-LYMPHOID LEUKEMIA PROTEIN; ONCOGENE PROTEINS, FUSION; OXIDOREDUCTASES, N-DEMETHYLATING; RNA, MESSENGER; RNA, NEOPLASM; RNA, SMALL INTERFERING; TUMOR STEM CELL ASSAY;

EID: 84897550318     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-08-522094     Document Type: Article

References (61)

1. de Boer J, Walf-Vorderwülbecke V, Williams O. In focus: MLL-rearranged leukemia. Leukemia. 2013;27(6):1224-1228.
2. Yip BH, So CWE. Mixed lineage leukemia protein in normal and leukemic stem cells. Exp Biol Med (Maywood). 2013;238(3):315-323.
3. Hilden JM, Dinndorf PA, Meerbaum SO, et al Children's Oncology Group. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group. Blood. 2006;108(2):441-451. (Pubitemid 44061340)
4. Tomizawa D, Koh K, Sato T, et al. Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects: a final report of two consecutive studies, MLL96 and MLL98, of the Japan Infant Leukemia Study Group. Leukemia. 2007;21(11):2258-2263. (Pubitemid 350011697)
5. Wang P, Lin C, Smith ER, et al. Global analysis of H3K4 methylation defines MLL family member targets and points to a role for MLL1-mediated H3K4 methylation in the regulation of transcriptional initiation by RNA polymerase II. Mol Cell Biol. 2009;29(22):6074-6085.
6. Deshpande AJ, Bradner J, Armstrong SA. Chromatin modifications as therapeutic targets in MLL-rearranged leukemia. Trends Immunol. 2012;33(11):563-570.
7. Bernt KM, Zhu N, Sinha AU, et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell. 2011;20(1):66-78.
8. Chang MJ, Wu H, Achille NJ, et al. Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes. Cancer Res. 2010;70(24):10234-10242.
9. Harris WJ, Huang X, Lynch JT, et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell. 2012;21(4):473-487.
10. Schenk T, Chen WC, Göllner S, et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med. 2012;18(4):605-611.
11. Zuber J, Shi J, Wang E, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 2011;478(7370):524-528.
12. Dawson MA, Prinjha RK, Dittmann A, et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature. 2011;478(7370):529-533.
13. Yokoyama A, Somervaille TCP, Smith KS, Rozenblatt-Rosen O, Meyerson M, Cleary ML. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell. 2005;123(2):207-218. (Pubitemid 41457212)
14. Neff T, Sinha AU, Kluk MJ, et al. Polycomb repressive complex 2 is required for MLL-AF9 leukemia. Proc Natl Acad Sci U S A. 2012;109(13):5028-5033.
15. Shi J, Wang E, Zuber J, et al. The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;Nras(G12D) acute myeloid leukemia. Oncogene. 2013;32(7):930-938.
16. Tan J, Jones M, Koseki H, et al. CBX8, a polycomb group protein, is essential for MLL-AF9-induced leukemogenesis. Cancer Cell. 2011;20(5):563-575.
17. Wang E, Kawaoka S, Yu M, et al. Histone H2B ubiquitin ligase RNF20 is required for MLL-rearranged leukemia. Proc Natl Acad Sci U S A. 2013;110(10):3901-3906.
18. Huang H, Jiang X, Li Z, et al. TET1 plays an essential oncogenic role in MLL-rearranged leukemia. Proc Natl Acad Sci U S A. 2013;110(29):11994-11999.
19. Daigle SR, Olhava EJ, Therkelsen CA, et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell. 2011;20(1):53-65.
20. Grembecka J, He S, Shi A, et al. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat Chem Biol. 2012;8(3):277-284.
21. McCabe MT, Ott HM, Ganji G, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 2012;492(7427):108-112.
22. Knutson SK, Warholic NM, Wigle TJ, et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci U S A. 2013;110(19):7922-7927.
23. Qi W, Chan H, Teng L, et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci U S A. 2012;109(52):21360-21365.
24. Phenylcyclopropylamine derivatives and their medical use. Oryzon Genomics, S.A. 2010. Patent application number PCT/EP2010/050697.
25. Zender L, Xue W, Zuber J, et al. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell. 2008;135(5):852-864.
26. Meacham CE, Ho EE, Dubrovsky E, Gertler FB, Hemann MT. In vivo RNAi screening identifies regulators of actin dynamics as key determinants of lymphoma progression. Nat Genet. 2009;41(10):1133-1137.
27. Bric A, Miething C, Bialucha CU, et al. Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. Cancer Cell. 2009;16(4):324-335.
28. Miller PG, Al-Shahrour F, Hartwell KA, et al. In Vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling. Cancer Cell. 2013;24(1):45-58.
29. Wilkinson AC, Ballabio E, Geng H, et al. RUNX1 is a key target in t(4;11) leukemias that contributes to gene activation through an AF4-MLL complex interaction. Cell Rep. 2013;3(1):116-127.
30. Guenther MG, Lawton LN, Rozovskaia T, et al. Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. Genes Dev. 2008;22(24):3403-3408.
31. Lee JW, Choi H-S, Gyuris J, Brent R, Moore DD. Two classes of proteins dependent on either the presence or absence of thyroid hormone for interaction with the thyroid hormone receptor. Mol Endocrinol. 1995;9(2):243-254.
32. Wolf SS, Patchev VK, Obendorf M. A novel variant of the putative demethylase gene, s-JMJD1C, is a coactivator of the AR. Arch Biochem Biophys. 2007;460(1):56-66. (Pubitemid 46482422)
33. Kim SM, Kim JY, Choe NW, et al. Regulation of mouse steroidogenesis by WHISTLE and JMJD1C through histone methylation balance. Nucleic Acids Res. 2010;38(19):6389-6403.
34. Kuroki S, Akiyoshi M, Tokura M, et al. JMJD1C, a JmjC domain-containing protein, is required for long-term maintenance of male germ cells in mice. Biol Reprod. 2013;89(4):93.
35. Brauchle M, Yao Z, Arora R, et al. Protein complex interactor analysis and differential activity of KDM3 subfamily members towards H3K9 methylation. PLoS ONE. 2013;8(4):e60549.
36. Dickins RA, Hemann MT, Zilfou JT, et al. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat Genet. 2005;37(11):1289-1295. (Pubitemid 41568715)
37. Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 2009;10(3):R25.
38. Nolan Lab website. Phoenix helper-free retrovirus producer lines. http://www.stanford.edu/group/nolan/retroviral-systems/phx.html.
39. Kingston RE, Chen CA, Rose JK. Calcium phosphate transfection. Current protocols in molecular biology. 2003;63:9.1.1-9.1.11.
40. Somervaille TCP, Cleary ML. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell. 2006;10(4):257-268. (Pubitemid 44512188)
41. Zuber J, Rappaport AR, Luo W, et al. An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. Genes Dev. 2011;25(15):1628-1640.
42. Gieger C, Radhakrishnan A, Cvejic A, et al. New gene functions in megakaryopoiesis and platelet formation. Nature. 2011;480(7376):201-208.
43. Mucenski ML, McLain K, Kier AB, et al. A functional c-myb gene is required for normal murine fetal hepatic hematopoiesis. Cell. 1991;65(4):677-689.
44. Balgobind BV, Zwaan CM, Reinhardt D, et al. High BRE expression in pediatric MLL-rearranged AML is associated with favorable outcome. Leukemia. 2010;24(12):2048-2055.
45. Trentin L, Giordan M, Dingermann T, Basso G, Te Kronnie G, Marschalek R. Two independent gene signatures in pediatric t(4;11) acute lymphoblastic leukemia patients. Eur J Haematol. 2009;83(5):406-419.
46. Ross ME, Mahfouz R, Onciu M, et al. Gene expression profiling of pediatric acute myelogenous leukemia. Blood. 2004;104(12):3679-3687. (Pubitemid 39564445)
47. Harvey RC, Mullighan CG, Wang X, et al. Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood. 2010;116(23):4874-4884.
48. Mullighan CG, Kennedy A, Zhou X, et al. Pediatric acute myeloid leukemia with NPM1 mutations is characterized by a gene expression profile with dysregulated HOX gene expression distinct from MLL-rearranged leukemias. Leukemia. 2007;21(9):2000-2009. (Pubitemid 47299976)
49. Thomas PD, Campbell MJ, Kejariwal A, et al. PANTHER: a library of protein families and subfamilies indexed by function. Genome Res. 2003;13(9):2129-2141. (Pubitemid 37161770)
50. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545-15550. (Pubitemid 41528093)
51. Somervaille TCP, Matheny CJ, Spencer GJ, et al. Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. Cell Stem Cell. 2009;4(2):129-140.
52. Jaatinen T, Hemmoranta H, Hautaniemi S, et al. Global gene expression profile of human cord blood-derived CD1331 cells. Stem Cells. 2006;24(3):631-641. (Pubitemid 44464767)
53. Acosta JC, Ferrándiz N, Bretones G, et al. Myc inhibits p27-induced erythroid differentiation of leukemia cells by repressing erythroid master genes without reversing p27-mediated cell cycle arrest. Mol Cell Biol. 2008;28(24):7286-7295.
54. Schuhmacher M, Kohlhuber F, Hölzel M, et al. The transcriptional program of a human B cell line in response to Myc. Nucleic Acids Res. 2001;29(2):397-406. (Pubitemid 32060926)
55. Kim J, Woo AJ, Chu J, et al. A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell. 2010;143(2):313-324.
56. Hess JL, Bittner CB, Zeisig DT, et al. c-Myb is an essential downstream target for homeobox-mediated transformation of hematopoietic cells. Blood. 2006;108(1):297-304. (Pubitemid 43990642)
57. Liu Y, Zhang W. Identification of a new transmembrane adaptor protein that constitutively binds Grb2 in B cells. J Leukoc Biol. 2008;84(3):842-851.
58. Can I, Tahara-Hanaoka S, Hitomi K, et al. Caspase-independent cell death by CD300LF (MAIR-V), an inhibitory immunoglobulin-like receptor on myeloid cells. J Immunol. 2008;180(1):207-213.
59. Ross ME, Zhou X, Song G, et al. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood. 2003;102(8):2951- 2959. (Pubitemid 37248870)
60. Krivtsov AV, Twomey D, Feng Z, et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature. 2006;442(7104):818-822. (Pubitemid 44258912)
61. Watanabe S, Watanabe K, Akimov V, et al. JMJD1C demethylates MDC1 to regulate the RNF8 and BRCA1-mediated chromatin response to DNA breaks. Nat Struct Mol Biol. 2013;20(12):1425-1433.